Interleukin Genetics is pioneering a new commercialization model in personalized medicine in which it is being bankrolled by insurers who see the potential for lowering healthcare costs through utilization of molecular diagnostics.
This article has been updated from an earlier version with additional comments from Eliot Lurier.
By Turna Ray
American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.
A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.
Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.